Cellular immunity elicited by the BioNTech/Pfizer and Johnson & Johnson Covid-19 vaccines is effective against the Omicron coronavirus variant, according to a study, suggesting vaccines will protect against severe disease even if the antibody responses against the strain are not as strong or durable.
一項研究表明，由BioNTech/輝瑞(Pfizer)和強生(Johnson & Johnson)新冠疫苗引發的細胞免疫對Omicron變種有效，這似乎表明現有疫苗能夠預防重癥——即便針對該病毒株的抗體反應不那么強烈或持久。
您已閱讀10%（413字），剩余90%（3870字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。